Posted by Michael Wonder on 28 Jun 2021
AskBio receives FDA fast track designation for LION-101, a novel investigational AAV gene therapy for the treatment of limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9)
28 June 2021 - LGMD2I/R9 is a rare form of muscular dystrophy with no approved therapies.
Asklepios BioPharmaceutical announced that the U.S. FDA has granted fast track designation for the LION-101 gene therapy program.
LION-101 is a novel recombinant adeno-associated virus based vector being developed as a one-time intravenous infusion for the treatment of patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).
